I presented data on the first international external validation of the MMAI test developed by Artera in a localized prostate cancer clinical trial. So we evaluated the test in almost 1,800 patients recruited to the CHIP trial of radiotherapy fractionation. And sort of one-line summary of what we showed is that MMAI, which is a digital pathology AI test, really improved prediction of which men would develop a rapid recurrence of their prostate cancer versus which men would have extremely good outcomes...
I presented data on the first international external validation of the MMAI test developed by Artera in a localized prostate cancer clinical trial. So we evaluated the test in almost 1,800 patients recruited to the CHIP trial of radiotherapy fractionation. And sort of one-line summary of what we showed is that MMAI, which is a digital pathology AI test, really improved prediction of which men would develop a rapid recurrence of their prostate cancer versus which men would have extremely good outcomes. An important aspect of our work was actually to say how much does the MMAI test add value to what we can already predict in clinic. So the statistical analyses that we did specifically looked at the added value of the MMAI test and what they showed and the particular metrics we used were the C index and the change in likelihood ratio was that across all the endpoints that we looked at relating to both biochemical or clinical recurrence and development of metastases, there was highly significant improvement in prediction of outcomes with the addition of the MMAI test.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
